New fibrinolytic agents for MI: as effective as current agents, but easier to administer.
The efficacy and safety of fibrinolytic agents have not dramatically changed since alteplase (Activase), a derivative of tissue plasminogen activator (t-PA), was introduced nearly 2 decades ago. However, newer agents have a longer half-life, making them easier to deliver. Fibrinolytic therapy is underused in many patients, especially in those traditionally thought to be at high risk for complications.
Ellis
Keith
K
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
Brener
Sorin
S
D000368:Aged; D000075202:Contraindications; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D000077785:Tenecteplase; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000639:trends*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C087896:reteplase; D010959:Tissue Plasminogen Activator; D000077785:Tenecteplase